UGT1A1 Genotype-Dependent Dose Adjustment of Belinostat in Patients With Advanced Cancers Using Population Pharmacokinetic Modeling and Simulation

Belinostat is a second-generation zinc-binding histone deacetylase inhibitor that is approved for peripheral T-cell lymphoma and is currently being studied in small cell lung cancer and other advanced carcinomas as a 48-hour continuous intravenous infusion. Belinostat is predominantly metabolized by...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Clin Pharmacol
Päätekijät: Peer, Cody J., Goey, Andrew K. L., Sissung, Tristan M., Erlich, Sheryl, Lee, Min-Jung, Tomita, Yusuke, Trepel, Jane B., Piekarz, Richard, Balasubramaniam, Sanjeeve, Bates, Susan E., Figg, William D.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2015
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6357964/
https://ncbi.nlm.nih.gov/pubmed/26637161
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.627
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia